Market Research Logo

Immunotherapy Drugs Market by Type of Drug (Monoclonal Antibodies, Interferon-Alpha, Interleukins, Vaccines, (Therapeutic Vaccines and Preventive Vaccines), Checkpoint Inhibitors), Epidemiology, Regulatory and Pipeline Analysis - Global Forecast to 2020

Immunotherapy Drugs Market by Type of Drug (Monoclonal Antibodies, Interferon-Alpha, Interleukins, Vaccines, (Therapeutic Vaccines and Preventive Vaccines), Checkpoint Inhibitors), Epidemiology, Regulatory and Pipeline Analysis - Global Forecast to 2020

The immunotherapy drugs market is broadly segmented on the basis of type of drugs and geographic region. The major type of immunotherapy drugs studied in the report includes antibodies (monoclonal and polyclonal), interferon (alpha), interleukins, vaccines, and checkpoint inhibitors. Among these types of drugs, monoclonal antibodies segment is expected to command the largest share while checkpoint inhibitors is expected to grow at the highest rate. This high growth rate is attributed to the technological advancement and higher efficacy of checkpoint inhibitors.

The immunotherapy drugs market, by geography, is classified into North America, Europe, Asia-Pacific, and Rest of the World. The North American geographic segment will account for the largest share of the global immunotherapy drugs market in 2015, followed by the Europe geographic segments. The Asia-Pacific segment is expected to account for highest CAGR of the immunotherapy drugs market in 2015. The major drivers for the growth of this market are increasing incidence of different types of cancer; focus on targeted therapies with fewer side effects and quicker drug approval processes.

From an insight perspective, this research report focuses on qualitative data, market size, growth of various segments and subsegments, competitive landscape, and company profiles. The qualitative data covers various levels of industry analysis such as market dynamics (drivers, restraints, opportunities, and threats). The report also offers market sizes and data of various segments in this industry. It focuses on emerging and high-growth segments, high-growth regions, and initiatives by governments. The competitive landscape covers the growth strategies adopted by industry players in the last three years. The company profiles comprise basic views on the key players in the immunotherapy drugs market and the strategies adopted by them to maintain and increase their market shares in the near future. The above-mentioned market research data, current market size, and forecast of the future trends will help key players and new entrants to make the necessary decisions regarding product offerings, geographical focus, change in approach, R&D investments for innovations in products and technologies, and levels of output in order to remain successful.

Reasons to Buy the Report:
This report will enable both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn will help these firms garner a greater market share. Firms purchasing the report can use any one or a combination of the below-mentioned five strategies (market penetration, product development/innovation, market development, market diversification, and competitive assessment) for strengthening their market shares.

The report provides insights on the following pointers:
Market Penetration: Comprehensive information on the product portfolios of the top players in the immunotherapy drugs market. The report analyzes the immunotherapy drugs market by technology, application, products & services, and end user

Product Development/Innovation: Detailed insights on upcoming technologies and R&D activities in the immunotherapy drugs market

Competitive Assessment: In-depth assessment of market strategies, geographic and business segments, and product portfolios of leading players in the immunotherapy drugs market

Market Development: Comprehensive information about emerging markets. This report analyzes the market for various products across geographies

Market Diversification: Exhaustive information on new products and services, untapped geographies, recent developments, and investments in the immunotherapy drugs market


  • INTRODUCTION
    • OBJECTIVES OF THE STUDY
    • MARKET DEFINITION
    • MARKET SCOPE
      • MARKETS COVERED
      • YEARS CONSIDERED FOR THE STUDY
    • CURRENCY
    • LIMITATIONS
    • STAKEHOLDERS
  • RESEARCH METHODOLOGY
    • MARKET SIZE ESTIMATION
    • MARKET BREAKDOWN AND DATA TRIANGULATION
      • KEY DATA FROM SECONDARY SOURCES
      • KEY DATA FROM PRIMARY SOURCES
      • ASSUMPTIONS FOR THE STUDY
  • EXECUTIVE SUMMARY
  • PREMIUM INSIGHTS
    • IMMUNOTHERAPY DRUGS MARKET TO GROW AT A RAPID RATE
    • GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE
    • GEOGRAPHICAL SNAPSHOT OF THE IMMUNOTHERAPY DRUGS MARKET
    • IMMUNOTHERAPY DRUGS MARKET, BY TYPE OF DRUG
    • LIFECYCLE ANALYSIS, BY REGION
  • MARKET OVERVIEW
    • INTRODUCTION
    • MARKET SEGMENTATION
    • MARKET DYNAMICS
    • DRIVERS
      • INCREASING ADOPTION OF TARGETED THERAPY OVER TRADITIONAL THERAPY
      • REDUCTION IN OVERALL TIMELINE AND COST FOR DRUG DISCOVERY
      • HIGH PREVALENCE RATE OF LIFESTYLE DISEASES
      • FAST TRACK AND ORPHAN DRUG DESIGNATIONS
    • RESTRAINTS
      • HIGH COST OF IMMUNOTHERAPY TREATMENT
      • HIGH ATTRITION RATE IN THE PRODUCT DEVELOPMENT CYCLE
    • OPPORTUNITIES
      • SIGNIFICANT GROWTH PROSPECTS IN DEVELOPING COUNTRIES
      • IMMUNOTHERAPY TO REPLACE CHEMOTHERAPY AS A FIRST-LINE THERAPY
    • CHALLENGES
      • PATENT EXPIRIES OF TOP-SELLING BIOLOGICS
  • CANCER IMMUNOTHERAPY MARKET- INDUSTRY INSIGHTS
    • CANCER EPIDEMIOLOGY
      • ESTIMATED INCIDENCE, MORTALITY, AND 5-YEAR PREVALENCE: MEN (2012)
      • ESTIMATED INCIDENCE, MORTALITY, AND 5-YEAR PREVALENCE: WOMEN
      • ESTIMATED INCIDENCE, MORTALITY, AND 5-YEAR PREVALENCE: BOTH SEXES (2012)
    • PRICING AND REIMBURSEMENT
      • U.S.
      • U.K.
      • FRANCE
      • GERMANY
      • OTHER EUROPEAN COUNTRIES
      • JAPAN
    • PIPELINE
      • PHASE 1
      • PHASE I/II
      • PHASE II
      • PHASE II/III
      • PHASE III
      • APPLICATION SUBMITTED
    • PROMISING MOLECULES
    • TREATMENT PROTOCOLS AND LINE OF THERAPIES
      • FIRST LINE THERAPY
      • SECOND LINE THERAPY
      • OTHER TREATMENTS
  • IMMUNOTHERAPY DRUGS MARKET, BY TYPE OF DRUGS
    • INTRODUCTION
      • Table GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE OF DRUG, 2013-2020 (USD MILLION)
    • MONOCLONAL ANTIBODIES
      • Table GLOBAL MONOCLONAL ANTIBODY DRUGS MARKET SIZE, BY REGION, 2013-2020 (USD MILLION)
      • Table NORTH AMERICA: MONOCLONAL ANTIBODY DRUGS MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
      • Table EUROPE: MONOCLONAL ANTIBODY DRUGS MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
      • Table ASIA-PACIFIC: MONOCLONAL ANTIBODY DRUGS MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
    • INTERFERONS
      • Table GLOBAL INTERFERON DRUGS MARKET SIZE, BY REGION, 2013-2020 (USD MILLION)
      • Table NORTH AMERICA: INTERFERON DRUGS MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
      • Table EUROPE: INTERFERON DRUGS MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
      • Table ASIA-PACIFIC: INTERFERON DRUGS MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
    • INTERLEUKINS
      • Table GLOBAL INTERLEUKIN DRUGS MARKET SIZE, 2013-2020 (USD MILLION)
    • VACCINES
      • Table GLOBAL VACCINES MARKET SIZE, BY REGION, 2013-2020 (USD MILLION)
      • Table GLOBAL VACCINES MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
      • Table NORTH AMERICA: VACCINES MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
      • Table EUROPE: VACCINES MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
      • Table ASIA-PACIFIC: VACCINES MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
    • CHECKPOINT INHIBITORS
      • Table GLOBAL CHECKPOINT INHIBITOR DRUGS MARKET SIZE, BY REGION, 2013-2020 (USD MILLION)
      • Table NORTH AMERICA: CHECKPOINT INHIBITOR DRUGS MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
      • Table EUROPE: CHECKPOINT INHIBITOR DRUGS MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
      • Table ASIA-PACIFIC: CHECKPOINT INHIBITOR DRUGS MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • GLOBAL IMMUNOTHERAPY DRUGS MARKET, BY REGION
    • INTRODUCTION
      • Table GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY REGION, 2013-2020 (USD MILLION)
    • NORTH AMERICA
      • Table NORTH AMERICA: IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE OF DRUG, 2013-2020 (USD MILLION)
      • U.S.
        • Table U.S.: IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE OF DRUG, 2013-2020 (USD MILLION)
      • CANADA
        • Table CANADA: IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE OF DRUG, 2013-2020 (USD MILLION)
    • EUROPE
      • Table EUROPE: IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE OF DRUG, 2013-2020 (USD MILLION)
      • GERMANY
        • Table GERMANY: IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE OF DRUG, 2013-2020 (USD MILLION)
      • U.K.
        • Table U.K.: IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE OF DRUG, 2013-2020 (USD MILLION)
      • FRANCE
        • Table FRANCE: IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE OF DRUG, 2013-2020 (USD MILLION)
      • ITALY
        • Table ITALY: IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE OF DRUG, 2013-2020 (USD MILLION)
      • SPAIN
        • Table SPAIN: IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE OF DRUG, 2013-2020 (USD MILLION)
    • ASIA-PACIFIC
      • Table APAC: IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE OF DRUG, 2013-2020 (USD MILLION)
      • JAPAN
        • Table JAPAN: IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE OF DRUG, 2013-2020 (USD MILLION)
      • CHINA
        • Table CHINA: IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE OF DRUG, 2013-2020 (USD MILLION)
      • INDIA
        • Table INDIA: IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE OF DRUG, 2013-2020 (USD MILLION)
    • REST OF THE WORLD (ROW)
      • Table ROW: IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE OF DRUG, 2013-2020 (USD MILLION)
  • COMPETITIVE LANDSCAPE
    • OVERVIEW
    • MARKET SHARE ANALYSIS
    • COMPETITIVE SITUATION AND TRENDS
      • APPROVALS
        • Table APPROVALS, 2013-2015
      • AGREEMENTS, PARTNERSHIPS, AND COLLABORATIONS
        • Table AGREEMENTS, PARTNERSHIPS, AND COLLABORATIONS, 2013-2015
      • ACQUSITIONS
        • Table ACQUSITIONS, 2013-2015
  • COMPANY PROFILES
    • INTRODUCTION
    • F. HOFFMANN-LA ROCHE AG
      • BUSINESS OVERVIEW
      • F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT
      • PRODUCTS OFFERED
      • RECENT DEVELOPMENTS
      • MNM VIEW
    • MERCK & CO., INC.
      • BUSINESS OVERVIEW
      • MERCK & CO., INC.: COMPANY SNAPSHOT
      • PRODUCTS OFFERED
      • RECENT DEVELOPMEN
      • MNM VIEW
    • NOVARTIS INTERNATIONAL AG
      • BUSINESS OVERVIEW
      • NOVARTIS INTERNATIONAL AG: COMPANY SNAPSHOT
      • PRODUCTS OFFERED
      • RECENT DEVELOPMENTS
      • MNM VIEW
    • GLAXOSMITHKLINE PLC
      • BUSINESS OVERVIEW
      • GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT
      • PRODUCT OFFERED
      • RECENT DEVELOPMENTS
      • MNM VIEW
    • AMGEN INC.
      • BUSINESS OVERVIEW
      • AMGEN INC.: COMPANY SNAPSHOT
      • PRODUCTS OFFERED
      • RECENT DEVELOPMENTS
      • MNM VIEW
    • BRISTOL-MYERS SQUIBB
      • BUSINESS OVERVIEW
      • BRISTOL-MYERS SQUIBB: COMPANY SNAPSHOT
      • PRODUCTS OFFERED
      • RECENT DEVELOPMENTS
    • ELI LILLY AND COMPANY
      • BUSINESS OVERVIEW
      • ELI LILLY AND COMPANY: COMPANY SNAPSHOT
      • PRODUCT OFFERED
      • RECENT DEVELOPMENTS
    • CELGENE CORPORATION
      • BUSINESS OVERVIEW
      • CELGENE CORPORATION: COMPANY SNAPSHOT
      • PRODUCTS OFFERED
      • RECENT DEVELOPMENT
    • SEATTLE GENETICS, INC.
      • BUSINESS OVERVIEW
      • SEATTLE GENETICS, INC.: COMPANY SNAPSHOT
      • PRODUCT OFFERED
      • RECENT DEVELOPMENTS
    • SPECTRUM PHARMACEUTICALS, INC.
      • BUSINESS OVERVIEW
      • SPECTRUM PHRMACEUTICALS, INC.: COMPANY SNAPSHOT
      • PRODUCT OFFERED
      • RECENT DEVELOPMENTS
  • APPENDIX
    • INSIGHTS OF INDUSTRY EXPERTS
    • DISCUSSION GUIDE
    • INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE
    • AVAILABLE CUSTOMIZATIONS
    • RELATED REPORTS

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report